SCHEMBL4740213

SCHEMBL4740213

O=c1cc(O)nc(C2CCCCC2)n1-c1cccc(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
HTT P42858 1/20 0.42
APLNR P35414 3/20 0.40
LMNA P02545 1/20 0.39
KCNJ6 P48051 1/20 0.39
KCNJ5 P48544 1/20 0.39
KCNJ3 P48549 1/20 0.39
MDM2 Q00987 2/20 0.39
DRD1 P21728 2/20 0.39
DRD5 P21918 2/20 0.39
POLB P06746 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4D Q08499 1/20 0.38
NOTUM Q6P988 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
ADORA2A P29274 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4739974 0.87 ALDH1A1 (0.38) KMT2AKDM4EALDH1A1MEN1USP2
SCHEMBL4739124 0.86 HPGD (0.43) KMT2AKDM4EALDH1A1MEN1USP2
SCHEMBL4737525 0.86 KMT2A (0.54) KMT2AKDM4EALDH1A1MEN1USP2
SCHEMBL4740337 0.85 KMT2A (0.42) KMT2AKDM4EALDH1A1MEN1USP2
SCHEMBL4782896 0.82 KMT2A (0.44) KMT2AKDM4EALDH1A1MEN1USP2
SCHEMBL4739113 0.82 MDM2 (0.47) KMT2AKDM4EALDH1A1MEN1USP2
SCHEMBL17317042 0.82 APLNR (0.51) KMT2AKDM4EALDH1A1MEN1USP2
SCHEMBL4741828 0.81 APLNR (0.44) KMT2AKDM4EALDH1A1MEN1USP2
SCHEMBL4786165 0.80 APLNR (0.52) KMT2AKDM4EALDH1A1MEN1USP2
SCHEMBL4741829 0.79 APLNR (0.50) KMT2AKDM4EALDH1A1MEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 KMT2A 734/4885KDM4E 746/4885ALDH1A1 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.